Investing.com - (NYSE:Abbott Labs) fourth quarter earnings in line with estimates as revenues fell short.
Abbott reported a 4.8% rise in diluted Q4 EPS to $0.65 on a year-on-year rise of 2.8% in revenues to $5.33 bn.
The consensus forecast for the U.S. pharmaceutical firm's revenues was $5.42 bn.
Full-year diluted EPS was up 2.3% at $2.20 as revenues rose 2.2% to $20.85 bn.
Abbott issued guidance for full-year diluted EPS of $2.40-$2.50.
Abbott's shares were down 0.77% at $40.00 in pre-market trade.